Individual

For people managing their own savings and investments.

Financial advisors and wealth managers

For people managing savings and/or investments on behalf of someone else.

Institutional

For pension schemes, insurers, charities, universities, family offices and treasurers.

Change country site
  1. Homepage
  2. Investment solutions

Aberdeen’s healthcare fund complex

Where expertise meets investment opportunity

Explore our fund rangeFund Overview (pdf)Opens in new window

Tune in to the latest insights on the Aberdeen Healthcare Funds!

Join Mike Taggart, Head of Closed-End Fund Investor Relations at Aberdeen, as he sits down with Jason Akus, Head of Healthcare Investments and Portfolio Manager, for an in-depth conversation about the current state of the healthcare marketplace. Whether you're an investor or simply curious about healthcare trends, this episode offers valuable perspectives straight from the experts. Don’t miss it—listen now!

Exploring the future: AI's transformative role in healthcare investing

By Jason Akus, Head of Healthcare Investments

In 2025, the healthcare landscape is set to be transformed by the Stargate project, a groundbreaking initiative powered by Oracle, OpenAI, and Softbank. This project promises to revolutionize cancer research and healthcare investing, harnessing the power of AI to drive unprecedented advancements. Learn more about how this new era of innovation may impact investment opportunities in the healthcare sector!

Find Out More

Healthcare fund information

Explore our range of closed-end healthcare funds, each with a distinct focus, all managed by seasoned professionals with deep expertise in the ever-evolving healthcare sector.

abrdn Healthcare Investors (HQH)

The Funds investment objective is to seek long-term capital appreciation by investing primarily in securities of healthcare companies. In addition, the Fund seeks to provide regular distribution of realized capital gains.

Find out moreOpens in new window
Scientist testing samples

abrdn Life Sciences Investors (HQL)

The Funds investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies.

Find out moreOpens in new window

abrdn Healthcare Opportunities Fund (THQ)

The Funds investment objective is to seek current income and long-term capital appreciation.

Find out moreOpens in new window

abrdn World Healthcare Fund (THW)

The Funds investment objective is to seek current income and long-term capital appreciation.

Find out moreOpens in new window

Related articles

Insights5 min Read

Healthcare: AI’s broader impact

A look at how artificial intelligence is revolutionizing healthcare, extending beyond cancer vaccines to offer transformative benefits in drug discovery, toxicology, and trial design.

Healthcare: AI’s broader impact
Insights4 min Read

Five fundamental attributes of closed-end funds

We explore how closed-end funds – offering a unique blend of features prized by both mutual fund and stock investors – can potentially enhance portfolios with distinctive advantages.

Five fundamental attributes of closed-end funds
Insights6 min Read

A new era: Healthcare investing and AI in 2025

A look at how the Stargate project, powered by Oracle, OpenAI, and Softbank, is set to revolutionize cancer research and healthcare investing in 2025.

A new era: Healthcare investing and AI in 2025
Insights3 min Read

Healthcare investing: Silver linings and cutting edges

Why we believe investing in healthcare – with an aging demographic and rapidly evolving landscape – can provide long-term tailwinds.

Healthcare investing: Silver linings and cutting edges
Insights3 min Read

Closed-end funds: A steady hand

Unlocking the underlying strength of closed-end funds as an asset class.

Closed-end funds: A steady hand
View all articles

Connect with Aberdeen’s Closed-End Fund Investor Relations Team

1-800-522-5465
Investor.Relations@abrdn.com

To learn about all Aberdeen’s Closed-End Funds visit Aberdeen’s Closed-End Fund Investor Center.

 

For more information on our company or products, please contact our client-service team on 1-800-522-5465 or by email.

Email us
Copyright © Aberdeen Group plc 2021-2025. All rights reserved.

Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund’s investment return and principal value will fluctuate so that an investor’s shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund’s portfolio. There is no assurance that the Fund will achieve its investment objective. Past performance does not guarantee future results.

International investing entails special risk considerations, including currency fluctuations, lower liquidity, economic and political risks, and differences in accounting methods; these risks are generally heightened for emerging market investments. Concentrating investments in a single region subjects the Fund to more volatility and greater risk of loss than geographically diverse funds. Equity stocks of small and mid-cap companies carry greater risk, and more volatility than equity stocks of larger, more established companies. Dividends are not guaranteed and a company’s future ability to pay dividends may be limited. The Fund’s use of leverage exposes the Fund to additional risks, including the risk that the costs of leverage could exceed the income earned by the Fund on the proceeds of such leverage. Fixed income securities are subject to certain risks including, but not limited to: interest rate (changes in interest rates may cause a decline in the market value of an investment), credit (changes in the financial condition of the issuer, borrower, counterparty, or underlying collateral), prepayment (debt issuers may repay or refinance their loans or obligations earlier than anticipated), and extension (principal repayments may not occur as quickly as anticipated, causing the expected maturity of a security to increase).

The above is for informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the investments mentioned herein. Aberdeen does not warrant the accuracy, adequacy or completeness of the information and materials contained in this document and expressly disclaims liability for errors or omissions in such information and materials. Some of this information may contain projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies. These statements are only predictions and actual events or results may differ materially. Any opinion or estimate contained above is made on a general basis and is not to be relied on by the reader as advice. Neither Aberdeen nor any of its agents have given any consideration to nor have they made any investigation of the investment objectives, financial situation or particular need of the reader, any specific person or for any loss arising whether directly or indirectly as a result of the reader, any person or group of persons acting on any information, opinion or estimate contained in this document.

Privacy and Cookies Policy
The attention of users is drawn to Aberdeen's Privacy and Cookies Policy, which includes details on the use of performance, identification and targeting cookies (both our own and third parties) to enhance the functionality of the web-site, to enable Aberdeen to monitor usage and to assist with future communications. By continuing to use this site users will be deemed to have accepted this policy and the use of cookies for these limited purposes only.

Business Continuity Management & Disaster Recovery Programs

There can be no assurance that the Board will maintain the Fund's distribution rate at a particular level, or that the Board will continue a managed distribution policy. Additionally, distributions may include return of capital as well as net investment income and capital gains. If the Fund's investments do not generate sufficient income, the Fund may be required to liquidate a portion of its portfolio to fund these distributions. If the Fund's distributions consist of a large amount of return of capital, it may result in a deterioration of the Fund's assets.

abrdn Inc. has been registered as an investment adviser under the Investment Advisers Act of 1940 since August 23, 1995.

In the United States, Aberdeen is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.

This site does not provide financial or investment advice and does not take into account the particular financial circumstances of individual investors. Before investing, investors should seek their own professional advice.

All information contained in this website is provided in good faith and is believed to be accurate and reliable at the time of compilation. The information in this website is provided "as is" and on an "as available" basis without warranties of any kind. Aberdeen does not warrant that the information on the Aberdeen website will be uninterrupted or error free, or that any information, software, or other material accessible from or related to the Aberdeen website is free of viruses, worms, or other harmful components.

Some of the documents on this website may contain links to information created and maintained by other, unaffiliated organizations. Aberdeen does not control, cannot guarantee, and is not responsible for the accuracy, timeliness, or the continued availability or existence of this outside information.